Dozens of obesity and diabetes treatments are in the pipeline, some of which may help people lose even more weight than existing drugs like semaglutide.
Healthcare company Ro just launched a GLP-1 supply tracker. Eli Lilly is working on one, too
The telehealth company's stock surged after the announcement
The Vermont senator is launching an investigation into why these game-changing diabetes and obesity drugs can cost more than $1,000 a month in America.
Plus: Why Ozempic and other new weight-loss drugs aren't likely to be a repeat of the fen-phen crisis.
New data from Eli Lilly suggests that Zepbound can help people lose weight and have fewer episodes of obstructive sleep apnea at the same time.
Some people fear that new obesity drugs will inevitably prove to be dangerous, but there are key distinctions from the fen-phen crisis of the 1990s.
In a new Oscar-themed commercial, the drugmaker is telling people to stay away from its blockbuster medications if they’re only looking to lose a few pounds.
Plus, a major development in the quest for nuclear fusion power.
Zepbound (tirzepatide) had striking effects on blood pressure in the latest trial data, in addition to helping people shed pounds.
More than a third of former semaglutide regained their shed pounds, however.
Popular weight loss drugs, painkillers, and other common medications are seeing their list prices go up this month.
The FDA said it has "not found evidence that use of these medicines causes suicidal thoughts or actions" though it's still investigating the matter.
Some adverse event reports link alopecia and suicide ideation to GLP-1 drug use, but the FDA says the reports do not prove causation.
Semaglutide and other new drugs are the real deal in obesity treatment, but there are many lingering questions about their future.
People who stopped taking Zepbound (tirzepatide) regained much of their lost weight within a year, while those on it kept losing more.
People given the highest doses of a CRISPR-based gene therapy saw a noticeable drop in their levels of LDL-C, which can help cause heart disease.
In clinical trials, Eli Lilly's tirzepatide was found to help people lose upwards of 20% of their weight in conjunction with diet and exercise.
Officials in Austria say residents were hospitalized with low blood sugar and seizures after taking what they thought was Ozempic, a weight loss drug.
People who already lost weight at first went on to shed substantially more pounds than those on a placebo, Eli Lilly's newest clinical trial found.
Mode
Follow us
